Zenith Drugs Past Earnings Performance
Past criteria checks 2/6
Zenith Drugs has been growing earnings at an average annual rate of 64.2%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 24.9% per year. Zenith Drugs's return on equity is 29.9%, and it has net margins of 4.5%.
Key information
64.2%
Earnings growth rate
64.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 24.9% |
| Return on equity | 29.9% |
| Net Margin | 4.5% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zenith Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 1,145 | 52 | 50 | 0 |
| 31 Mar 22 | 917 | 31 | 38 | 0 |
| 31 Mar 21 | 734 | 30 | 36 | 0 |
| 31 Mar 20 | 783 | 34 | 49 | 0 |
| 31 Mar 19 | 522 | 11 | 29 | 0 |
| 31 Mar 18 | 368 | 8 | 16 | 0 |
Quality Earnings: ZENITHDRUG has a high level of non-cash earnings.
Growing Profit Margin: ZENITHDRUG's current net profit margins (4.5%) are higher than last year (3.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ZENITHDRUG's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare ZENITHDRUG's past year earnings growth to its 5-year average.
Earnings vs Industry: ZENITHDRUG earnings growth over the past year (64.2%) exceeded the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: Whilst ZENITHDRUG's Return on Equity (29.86%) is high, this metric is skewed due to their high level of debt.